Literature DB >> 18812232

Characterization of endothelial thromboxane receptors in rabbit aorta.

Sandra L Pfister1.   

Abstract

An increased synthesis of thromboxane (TX) A(2) is associated with a number of cardiovascular diseases including atherosclerosis, unstable angina and hypertension. We previously identified a subgroup of NZW rabbits in which isolated arteries failed to contract to the TX agonists, U46619 or I-BOP. In vascular smooth muscle membranes, there was a significant decrease in TX receptors, termed TP. These rabbits are referred to as vTP- and those with the TP receptor are called vTP+. Because TP receptors are expressed in some types of endothelial cells, the present study was designed to determine whether functional TP receptors are present in endothelial cells cultured from aortas of vTP+ and vTP- rabbits. Radioligand binding studies were performed with (125)I-BOP. Aortic endothelial cells from vTP+ rabbits exhibited specific and saturable binding. In contrast, in endothelial preparations from vTP- rabbit aortas, no measurable binding to (125)I-BOP was detected. Using an anti-TP receptor antibody, we compared the amount of receptor expressed in endothelial cell lysates obtained from vTP+ and vTP- rabbits. Consistent with the results observed radioligand binding assays, the expression of TP receptor protein was decreased in vTP- compared to vTP+ endothelial cells. An in vitro wound healing assay was used on confluent monolayers of endothelial cells. In the untreated vTP+ cells, the area of the scratch was completely closed by 30 h. In the vTP+ cells treated with U46619 (3 microM), the rate of closure of the scratch area was reduced with approximately 12% of the scratch area remaining at 30 h. Pretreatment with the TP receptor antagonist, SQ 29548 (10 microM) prevented the inhibitory effect of U46619. The rate of closure of the scratch in the vTP- was not altered by U46619. In a separate study, U46619 (3 microM) increased the release of 6-keto PGF(1alpha), the stable metabolite of prostacyclin, in vTP+ but not vTP- endothelial cells. Pretreatment with SQ29548 (10 microM) or the cyclooxygenase inhibitor, indomethacin (10 microM) blocked the increase in vTP+ endothelial cells. In vascular reactivity studies in aortas from vTP+ rabbits, removal of the endothelium enhanced the vasoconstrictor response to U46619 indicating that activation of endothelial TP receptors may modulate vascular tone via the release of the vasodilator, prostacyclin. The results of this study suggest an important role for endothelial TP receptors in modulating vascular function.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18812232      PMCID: PMC2584166          DOI: 10.1016/j.prostaglandins.2008.08.002

Source DB:  PubMed          Journal:  Prostaglandins Other Lipid Mediat        ISSN: 1098-8823            Impact factor:   3.072


  45 in total

1.  Inhibition of endothelial cell migration, intercellular communication, and vascular tube formation by thromboxane A(2).

Authors:  A W Ashton; R Yokota; G John; S Zhao; S O Suadicani; D C Spray; J A Ware
Journal:  J Biol Chem       Date:  1999-12-10       Impact factor: 5.157

Review 2.  Thromboxane A(2) receptors: where have you gone?

Authors:  P V Halushka
Journal:  Prostaglandins Other Lipid Mediat       Date:  2000-03       Impact factor: 3.072

3.  The alpha, but not the beta, isoform of the human thromboxane A2 receptor is a target for prostacyclin-mediated desensitization.

Authors:  M T Walsh; J F Foley; B T Kinsella
Journal:  J Biol Chem       Date:  2000-07-07       Impact factor: 5.157

Review 4.  Cell signalling through thromboxane A2 receptors.

Authors:  Jin-Sheng Huang; Santosh K Ramamurthy; Xin Lin; Guy C Le Breton
Journal:  Cell Signal       Date:  2004-05       Impact factor: 4.315

5.  Thromboxane A2 receptor signaling inhibits vascular endothelial growth factor-induced endothelial cell differentiation and migration.

Authors:  Anthony W Ashton; J Anthony Ware
Journal:  Circ Res       Date:  2004-07-08       Impact factor: 17.367

6.  Investigation of the role of the carboxyl-terminal tails of the alpha and beta isoforms of the human thromboxane A(2) receptor (TP) in mediating receptor:effector coupling.

Authors:  M Walsh; J F Foley; B T Kinsella
Journal:  Biochim Biophys Acta       Date:  2000-04-17

7.  Reversal of angiogenesis in vitro, induction of apoptosis, and inhibition of AKT phosphorylation in endothelial cells by thromboxane A(2).

Authors:  Y Gao; R Yokota; S Tang; A W Ashton; J A Ware
Journal:  Circ Res       Date:  2000-10-27       Impact factor: 17.367

8.  Cerivastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase, inhibits endothelial cell proliferation induced by angiogenic factors in vitro and angiogenesis in in vivo models.

Authors:  Loïc Vincent; Claudine Soria; Farrokh Mirshahi; Paule Opolon; Zohair Mishal; Jean-Pierre Vannier; Jeannette Soria; Li Hong
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-04-01       Impact factor: 8.311

Review 9.  Nitric oxide: a physiological mediator of the type 2 (AT2) angiotensin receptor.

Authors:  R M Carey; X Jin; Z Wang; H M Siragy
Journal:  Acta Physiol Scand       Date:  2000-01

10.  Differential regulation of RhoA-mediated signaling by the TPalpha and TPbeta isoforms of the human thromboxane A2 receptor: independent modulation of TPalpha signaling by prostacyclin and nitric oxide.

Authors:  Katarina Wikström; David J Kavanagh; Helen M Reid; B Therese Kinsella
Journal:  Cell Signal       Date:  2008-05-23       Impact factor: 4.315

View more
  2 in total

1.  Comparative analysis of myometrial and vascular smooth muscle cells to determine optimal cells for use in drug discovery.

Authors:  Shajila Siricilla; Kelsi M Knapp; Jackson H Rogers; Courtney Berger; Elaine L Shelton; Dehui Mi; Paige Vinson; Jennifer Condon; Bibhash C Paria; Jeff Reese; Quanhu Sheng; Jennifer L Herington
Journal:  Pharmacol Res       Date:  2019-05-09       Impact factor: 7.658

2.  Hypercholesterolemia and microvascular dysfunction: interventional strategies.

Authors:  Phoebe A Stapleton; Adam G Goodwill; Milinda E James; Robert W Brock; Jefferson C Frisbee
Journal:  J Inflamm (Lond)       Date:  2010-11-18       Impact factor: 4.981

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.